Breaking News, Collaborations & Alliances

Novo Nordisk Axes Relationship with Hims & Hers

Claims that knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers not authorized or inspected by the FDA.

Author Image

By: Charlie Sternberg

Associate Editor

After less than two months, Novo Nordisk has ended its partnership with Hims & Hers Health, Inc., citing “deceptive marketing” and the selling of “knock-off compounded versions” of its obesity drug, Wegovy. As a result, direct access to Wegovy will no longer be available to Hims & Hers Health Inc. via NovoCare Pharmacy. According to Novo Nordisk, Hims & Hers Health, Inc. has failed to adhere to a law that prohibits mass sales of compounded drugs under the false guise of “per...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters